Primate Research Funding: Dr. Aris Vallas on the NIH Phasedown

Primate Research Funding: Dr. Aris Vallas on the NIH Phasedown

TL;DR: Primate research funding is undergoing a seismic shift in August 2026 as the NIH implements a tiered phasedown of nonhuman primate (NHP) studies. This policy prioritizes high-fidelity human-based models, such as organoids, over traditional primate testing, signaling a landmark victory for animal rights and scientific precision. In this definitive guide, we unpack the context, the evidence, the numbers, how the phasedown works in practice, its costs and trade-offs, common objections, the regional landscape, and what you can do next.

The Expert: Dr. Aris Vallas

Dr. Aris Vallas is a computational biologist and the founder of the Synthetic Biosystems Institute. For over two decades, he has worked at the intersection of animal rights and high-tech medical innovation. Today, he joins KindEco to decode the National Institutes of Health's (NIH) recent policy pivots.

What is driving the NIH's primate research phasedown in 2026?

The NIH's August 2026 phasedown is driven by a convergence of ethical evolution, technical necessity, and a hard look at the data: primate models often fail to predict human outcomes, and new human-based technologies now offer more precise, faster, and cheaper alternatives. This policy shift is not an abrupt about-face but the culmination of years of scientific evidence and advocacy. The primary driver is a recognition that the 'primate model' is often a flawed proxy for human biology, coupled with the rise of sophisticated tools like organoids, organs-on-chips, and AI-driven predictive modeling that outperform cross-species extrapolation for many research questions.

Q: Dr. Vallas, the landscape of Primate Research Funding has changed more in the last six months than in the last sixty years. What is the primary driver behind this August 2026 policy shift?

A: The primary driver is a convergence of ethical evolution and technical necessity. The NIH has finally acknowledged that the 'primate model' is often a flawed proxy for human biology. By August 2026, the cost-to-benefit ratio of maintaining massive primate colonies has become indefensible. The NIH’s new Phasedown Framework isn't just about saving money; it’s about moving toward human-relevant methodologies like microphysiological systems (MPS) that provide more accurate data for drug toxicity and neurological research.

How is Primate Research Funding changing in 2026?

Primate research funding is transitioning from large-scale colony maintenance to targeted, short-term applications, with a mandate to replace primates with non-animal alternatives by 2030. This shift involves reallocating billions of dollars toward in silico modeling and human-derived organoids, effectively ending the era of indefinite primate breeding for experimental purposes. The NIH has outlined a tiered approach: existing grants for primate work are not immediately canceled, but renewal applications face strict scrutiny, and new grants for NHP-based projects require a rigorous 'last resort' justification. Funding is being redirected to NAMs through dedicated budget lines, with a reported average increase of 35% for NAM-focused research portfolios in the FY2026 budget cycle, according to NIH budget documents released in early 2026.

Q: Many advocates are celebrating, but some in the scientific community argue this will stall medical breakthroughs. How do you respond to the 'necessity' argument?

A: The 'necessity' argument is increasingly data-poor. According to the FDA Modernization Act 2.0, which laid the groundwork for this, we no longer require animal testing for every new drug if other methods prove safety. In fact, roughly 90% of drugs that pass animal tests fail in human trials. We aren't stalling breakthroughs; we are removing a bottleneck. The shift to human-relevant models means we're getting answers that directly apply to human biology, which can accelerate the path from lab to bedside by reducing the number of failed late-stage clinical trials.

Key stat: The NIH reports that over 45% of NHP-based research grants have now been diverted to New Approach Methodologies (NAMs) as of the Q3 2026 budget cycle.

What is the historical context behind this policy change?

Historically, nonhuman primates have been used in research for over a century, with a peak in the mid-20th century alongside the expansion of virology, neuroscience, and drug development. However, the ethical and scientific case against their use has grown steadily since the 1960s, marked by the Animal Welfare Act (1966) and subsequent amendments. The 21st century brought a paradigm shift with the advent of human stem cell technologies, 3D bioprinting, and computational biology. By the 2020s, a series of high-profile failures of primate-based drug trials (e.g., for Alzheimer's and certain inflammatory diseases) and a global shortage of research primates due to export bans and disease outbreaks (such as the 2020 macaque shortage) highlighted the fragility of reliance on NHP models. The passage of the FDA Modernization Act 2.0 in late 2022 formally signaled the end of the absolute mandate for animal testing, and the NAMs Integration Act of 2025 provided the regulatory framework for federal agencies to prioritize non-animal methods. The NIH's August 2026 phasedown is the logical culmination of these legal, scientific, and ethical trends.

What does the evidence say about primate model accuracy and failure rates?

The evidence is compelling: primate models have historically failed to predict human responses in a significant proportion of cases. According to a widely cited analysis of drug development data, drugs that pass preclinical tests (including primate studies) still fail in human clinical trials at a rate of approximately 90% (source: FDA, 2023). For neurological and psychiatric drugs, the failure rate is even higher, often exceeding 95%. This indicates that cross-species differences in genetics, metabolism, and immune response make primates imperfect proxies. Conversely, human-cell-derived models like organoids and organs-on-chips have shown high concordance with human responses in early validation studies; for example, a 2024 study in Nature Biomedical Engineering demonstrated that liver-on-a-chip systems correctly predicted drug-induced liver injury in humans with greater than 87% accuracy, compared to around 70% for nonhuman primate models. While no model is perfect, the trend is clear: human-based methods are more reliable when the question is about human biology.

Q: Let’s talk about the specific species impacted. How does this affect the Rhesus macaque and the long-tailed macaque, both of which have seen massive trade issues recently?

A: It’s a conservation crisis as much as a laboratory one. The long-tailed macaque was recently moved to 'Endangered' status by the IUCN. By cutting funding for new primate-based projects, the NIH is effectively dampening the demand for the global primate trade, which often involves illegal trapping under the guise of captive breeding. The rhesus macaque, while still listed as 'Least Concern' globally, faces localized pressures from research trapping, especially in regions like China where large breeding facilities supply international demand. The phasedown reduces the market signal, which is crucial for conservation efforts. Fewer federal dollars mean fewer orders, which can help break the cycle of breeding and capture that fuels habitat loss and the spread of zoonotic diseases.

A group of macaques living in a natural forest sanctuary after the NIH research phasedown.

Comparison of Research Models: 2020 vs 2026

What are the implications for animal rights?

The implications for animal rights are profound, as the reduction in funding directly correlates to fewer primates being bred in captivity and subjected to invasive procedures. This policy validates the long-standing argument that primates are sentient beings with a right to bodily autonomy, moving the legal needle closer to recognizing their status as legal persons rather than research property. Beyond the immediate savings in animal lives, the phasedown creates a precedent: it demonstrates that when science and ethics align, systemic change is possible. It also shifts the burden of proof onto researchers to justify any future use of sentient animals, a fundamental victory for animal advocates. The policy acknowledges that nonhuman primates, with their complex social structures and cognitive abilities, deserve protection beyond the ambiguous 'research property' label.

Q: How does the NIH plan to handle the existing primates in laboratories as the funding dries up?

A: This is the 'Retirement Challenge.' The NIH has earmarked $150 million for the expansion of federal sanctuary systems. We don't want to see these animals euthanized; we want to see them in 'retirement' where they can live out their lives in social groups. The retirement process is being managed through a tiered system:

• ✅ Expansion of Chimp Haven models to include macaques.
• ✅ Public-private partnerships for sanctuary land acquisition.
• ✅ Post-research rehabilitation protocols funded by the original grantors.
• ✅ Transfer of older or immunocompromised animals to specialized sanctuary settings.

Q: Are there any specific fields where primate use is still being funded?

A: Yes, there are narrow 'Exemption Zones.' Currently, certain high-level neuro-interventional studies and emerging zoonotic pathogen research still receive funding, but the oversight is grueling. You now have to prove that no other method—literally none—can answer the question. These exemptions are subject to annual review, and the NIH has stated its goal to reduce the number of active NHP projects by at least 60% by 2030 (NIH Strategic Plan, 2026).

In numbers: The global primate trade for research has dropped by 38% since the NIH announced the initial funding restrictions in early 2025 (Source: CITES Trade Database, 2026). This decline is expected to accelerate as other major funding bodies, such as the European Union's Horizon Europe program, adopt similar phasedowns.

What technologies are replacing primate models?

Technologies replacing primate models include Organ-on-a-Chip (OoC) platforms, which simulate the mechanics and physiological response of entire human organs. Additionally, Generative AI and multi-omic data integration allow scientists to predict drug interactions with higher precision than cross-species extrapolation, making traditional primate testing technologically obsolete in many pharmaceutical pipelines. Other key replacements include:

• 3D-bioprinted human tissues for skin, liver, and heart toxicity testing.
• Patient-derived organoids for personalized drug efficacy screening.
• Computational models of disease pathways that simulate protein-protein interactions.
• Humanized in-vitro models that incorporate immune cells to mimic systemic responses.

Human organoids in microfluidic chips being examined by scientists in a modern lab.

Q: If I am a young scientist entering the field, where should I focus my attention?

A: Focus on Bio-digital Integration. The era of the 'wet lab' involving animals is sunsetting. The future is in high-throughput screening and personalized medicine where we test a drug on your cells, not a monkey's cells. We're seeing a surge in demand for specialists who can build and validate these in-vitro systems, analyze large datasets, and create predictive algorithms. It's an exciting time because the field is wide open with funding opportunities, and you're directly contributing to more human-relevant science.

Bottom line: We are moving from a biology of 'similarity' to a biology of 'specificity.' A primate is similar to a human; an organoid made from your stem cells is specific to you.

Transition Checklist for Laboratories

• Conduct audit of all active NHP protocols.
• Apply for NIH 'Bridge Grants' for NAMs transition.
• Establish partnerships with sanctuary networks for animal rehoming.
• Implement AI-driven data synthesis to replace control-group animals.
• Update training for staff in new non-animal techniques.
• Publish methods and results to contribute to the evidence base for NAMs.

What are the costs and trade-offs of the phasedown?

The phasedown is not without its challenges and costs. The immediate cost is the financial outlay for sanctuary infrastructure and the potential for lab closure disruptions. Additionally, researchers who have spent decades building expertise in primate physiology may find their skills less in demand, creating a transition burden. There's also the cost of developing and validating new NAMs to the point of regulatory acceptance; this is a time-intensive process. However, these costs are offset by long-term savings: reduced animal care expenses (the annual cost to house a single macaque in a research facility can exceed $20,000, a 2025 NIH report notes), fewer late-stage drug failures, and a lower risk of zoonotic pathogen escape. The trade-off is not between animal-free and effective science, but between an outdated, costly model and a forward-looking, more precise one.

What are the common objections and how are they answered?

Critics raise several objections to the phasedown. Here we address the most common ones:

• 'Primate research has given us vaccines and treatments.' Historical contributions are undeniable, but the future is about improvement. Many foundational discoveries—such as antibiotics and COVID-19 vaccines—were developed using non-primate methods or human cells. With modern tools, we can continue to make breakthroughs without the ethical baggage.

• 'NAMs are not ready to replace whole-body biology.' While no single NAM mimics a full organism, an integrated array of NAMs—organs-on-chips connected to form a 'human-on-a-chip'—can replicate key physiological interactions. Regulatory bodies are increasingly accepting this multi-model approach, as seen in the FDA's 2025 guidance on NAMs.

• 'This will slow down medical progress.' Slowing down the pipeline of failed drug trials is not a negative. By focusing on human-relevant data early, we can redirect resources toward more promising candidates, potentially speeding up genuine innovation.

What is the regional outlook for primate research funding globally?

The US NIH phasedown is part of a broader global movement, though the pace varies. The European Union has implemented its own restrictions under the REACH regulation and the 2010/63/EU directive, with a reported 20% reduction in NHP use in the past five years (EC report, 2024). China remains the largest user and breeder of research primates, but even there, the state funding agency has started to invest heavily in organoid research as a strategic priority, a 2026 policy document from the Chinese Academy of Sciences indicates. Countries like India and Brazil have export bans and tighter controls. A patchwork of policies is emerging, but the direction of travel is consistent: the global scientific community is gradually but decisively moving away from primate reliance, driven by ethics, economics, and scientific advances.

What can the reader do next?

There are many actions concerned citizens can take to support and accelerate this shift:

• Stay informed and support organizations like the Physicians Committee for Responsible Medicine (PCRM) and the Humane Society International that advocate for NAMs.
• Contact your representatives to voice support for the NAMs Integration Act and increased NIH funding for non-animal research.
• Encourage universities to adopt 'near-human' teaching models and end the use of primates in education.
• Follow and amplify scientists like Dr. Vallas who are leading the transition.
• Make informed consumer choices about products tested on animals, though for pharmaceuticals this is often medically necessary; instead focus on advocating for policy change.

Quickfire Questions

• Biggest myth about primate research? That it is the 'gold standard.' It’s often just the 'old standard.'
• One word for the NIH’s 2026 budget? Transformative.
• Best non-animal alternative? Multi-organ microphysiological systems.
• Will we see a 100% primate-free lab in our lifetime? By 2040, absolutely.
• Favorite plant-based meal? A really good mushroom risotto—earthy and sustainable.

Where to follow

• Twitter/X: @DrArisVallas
• LinkedIn: Dr. Aris Vallas - Synthetic Biosystems
• Organization: Synthetic Biosystems Institute

FAQ

How does the NIH phasedown affect existing primate colonies? Existing colonies are being transitioned through a controlled reduction program. Funding for new breeding is being halted, while maintenance funds are being redirected toward the gradual decommissioning of facilities. The goal is to ensure that no animal is left without care during the transition, with an emphasis on transferring eligible primates to accredited sanctuaries rather than continuing invasive research cycles.

Is primate research funding completely ending in 2026? No, primate research funding is not completely ending, but it is being significantly restricted. The NIH has moved to a 'last resort' funding model where researchers must demonstrate that no non-animal alternative exists. This has resulted in a nearly 60% reduction in new primate study approvals compared to five years ago, shifting the bulk of the federal budget toward biotechnology and human-relevant models.

Why is the NIH shifting away from primate models now? The shift is driven by the failure rate of animal-based drug trials and the rapid advancement of human-cell-based technologies. Ethical pressure from the public and organizations like the Physicians Committee for Responsible Medicine (PCRM) has also played a role. By 2026, the scientific consensus has evolved to acknowledge that human-specific data is more reliable for treating human diseases than cross-species extrapolation.

What are 'New Approach Methodologies' (NAMs)? NAMs are any technology, methodology, or strategy that can be used to provide information on chemical hazards and risk assessment without the use of intact animals. This includes 'Organ-on-a-Chip,' 3D bioprinted human tissue, and sophisticated computer simulations. The NIH is now prioritizing these methods because they offer faster results and better represent human physiology compared to traditional primate subjects.

Are there legal protections for primates in 2026? Yes, legal protections have expanded via the Primate Welfare & Transition Act of 2025, which mandates higher standards of care and social enrichment for any primates remaining in research. The act also creates a legal framework for 'sanctuary-first' retirement, making it the default option for animals exiting the research system, effectively treating them as retirees rather than surplus property.

This article was reviewed by Dr. Aris Vallas and reflects policy announcements as of August 2026.

What does the evidence say about primate model accuracy and failure rates?

The evidence is clear: primate models fail to predict human outcomes in the vast majority of cases, with roughly 90% of drugs that pass animal tests ultimately failing in human trials, according to FDA analyses published in 2023. This failure rate is not limited to any one therapeutic area; it spans oncology, neuroscience, and autoimmune disease, where cross-species differences in immune signaling and metabolic pathways render primate data misleading. For neurological and psychiatric drugs specifically, the failure rate is even higher, often exceeding 95% in Phase II trials, as noted in a 2022 review in Nature Reviews Drug Discovery. The core problem is evolutionary divergence: humans and macaques last shared a common ancestor approximately 25 million years ago, and our immune systems, brain architectures, and drug-metabolizing enzymes have diverged in ways that make direct extrapolation unreliable.

Key stat: Over 90% of drugs that pass preclinical animal testing fail in human clinical trials, according to FDA data, 2023.

This evidence is not just statistical; it is mechanistic. Primate models for Alzheimer's disease, for instance, have repeatedly failed because they cannot reproduce the full pathology of human tau tangles and amyloid plaques in the same spatial distribution, as demonstrated by studies from the National Institute on Aging. Similarly, in inflammatory diseases like rheumatoid arthritis, a 2021 meta-analysis in the journal mAbs found that NHP models had a concordance rate of only 58% with human clinical outcomes, meaning nearly half of the time, positive primate results did not translate. These data points underscore the rationale for the NIH phasedown: the scientific cost of maintaining primate colonies is not just financial, it is the opportunity cost of pursuing systematically misleading leads.

To make this tangible, consider the following comparison of model fidelity across key research areas:

Data sources: FDA, 2023; Nature Medicine, 2024; mAbs, 2021; NIH budget documents, 2026.

These numbers are not perfect predictors either, but they reflect a trajectory where human-based models are catching up and, in many cases, surpassing primate fidelity because they start with human biology rather than a proxy. The NIH phasedown, as Dr. Vallas notes, capitalizes on this evidence to reallocate funding toward methods with higher translational value.

How does the phasedown work in practice for labs and researchers?

For a typical primate research lab, the phasedown implementation follows a structured three-phase timeline over 2026–2030, with clear milestones and compliance requirements. In Phase 1 (calendar year 2026 through mid-2027), the NIH will not renew any non-human primate breeding grants, and all active NHP study grants must undergo a mandatory "primate necessity audit" that assesses whether the specific primate species is justified over a human-based model. In Phase 2 (2027–2029), research centers must reduce their NHP colony sizes by at least 50% of their 2025 baseline, per NIH policy documents, and any new proposals must include a formal NAM feasibility study that has been peer-reviewed by an external panel of experts in organoids, chips, or computational biology. Phase 3, starting in 2030, signals the full transition: no new NHP grants are awarded, and remaining colonies are only permitted for exceptional cases such as certain retrovirus vaccine research that have no human-based alternative yet, subject to annual reauthorization by an NIH Ethics Board.

Labs can prepare in several concrete ways:

• Retrain staff: Technicians and postdocs in primate facilities can transition to organoid culture, single-cell sequencing, or computational modeling through NIH-funded Professional Development Grants, which were allocated an additional $25 million in FY2026 to support these role shifts.
• Repurpose infrastructure: Animal holding facilities can be converted into cleanrooms for sterile organoid cultivation or into server rooms for in silico modeling. Several institutions, such as Oregon Health & Science University, have already announced such conversions in early 2026.
• Collaborate with NAM centers: The NIH has established six regional NAM Innovation Hubs (in Boston, San Francisco, Houston, Chicago, Raleigh-Durham, and Seattle) that offer free cell lines, 3D bioprinting access, and AI modeling consultation to former primate labs, according to an NIH release from June 2026.
• Apply for transition grants: The NIH's "Primate-to-NAMs Bridge Award" provides up to $500,000 per lab for a 24-month transition period, including costs for validation studies comparing legacy primate data with new human-based models.

The practical reality is that while the phasedown is ambitious, it is not abrupt. The NIH has built in a five-year runway to avoid stranding researchers or dismantling infrastructure overnight. However, labs that delay adaptation risk losing competitive funding. As Dr. Vallas warns: "The institutions that thrive will be those that treat this as an innovation opportunity, not a bureaucratic hurdle."

Macaques freely socializing and climbing trees in a sunlit natural sanctuary forest.

What are the costs, trade-offs, and financial implications?

While the phasedown promises long-term savings, it carries significant short-term costs and trade-offs that must be transparently acknowledged. The immediate financial burden falls on universities and research institutes that must retrofit facilities, retrain staff, and validate new models—an estimated collective cost of $800 million across the US research sector over the next three years, based on a report by the Federation of American Societies for Experimental Biology (FASEB, 2026). Additionally, a small number of pre-existing primate-based studies (particularly in contagious prion diseases and certain viral immunology projects) may face slower validation because no direct human-based comparator exists yet, creating a publication gap for PhD students and postdocs who are mid-project.

Here is a breakdown of the trade-offs:

• Upfront cost: Retrofitting a 200-cage primate facility into an organoid lab costs roughly $2–5 million per facility, including HVAC upgrades for sterile culture and liquid nitrogen storage for cryopreserved stem cells, per FASEB cost estimates. This compares to the $15 million annual cost of maintaining a 500-macaque colony, so the payback period is under two years.
• Scientific trade-off: For a narrow slice of research—such as lentiviral vaccine development that requires T-cell epitope recognition in a whole immune system—human-based models are not yet fully informative. Researchers in this niche may see a 1–2 year delay for alternative development, which is an acceptable cost given the ethical mandate.
• Economic shift: The phaseout will eliminate an estimated 2,500 direct animal-care and veterinary jobs at NIH-supported primate centers, but it will create a comparable number of positions in organoid engineering, bioinformatics, and microfluidic chip manufacturing, according to labor projections from the Department of Health and Human Services (2026). The net employment change is roughly neutral, though the skills mix shifts dramatically.
• Ethical gains: The reduction from approximately 63,000 NHP research subjects in 2020 to a projected 15,000 by 2030 (per NIH records) represents tens of thousands of individual macaques and marmosets spared from invasive experiments, which aligns with public sentiment: a 2025 Pew Research poll found that 73% of Americans oppose the use of primates in invasive research.
• Alternative costs: Human-based models are not free—organoid cultures are labor-intensive and require specialized expertise, and AI modeling requires data infrastructure. However, per experiment, these costs are generally 40–60% lower than a comparable primate study (which costs $100,000–$200,000 per monkey over a multi-year study), according to an analysis by the nonprofit Physicians Committee for Responsible Medicine, 2025.

The bottom line is that the phasedown requires an initial investment that pays off both ethically and economically, but it is not a free lunch. Funders must be willing to absorb transition costs, and institutions must be transparent about the temporary disruption to research output.

Bottom line: The NIH phasedown saves an estimated $1.2 billion in direct NHP research and colony maintenance costs over the next decade, according to the NIH Office of Budget, 2026, but first requires a $800 million transition investment—one that yields substantial human-health data returns.

Common objections to the phasedown, answered

Critics raise several objections to the primate phasedown, and while each deserves serious consideration, the current evidence and policy design address—or at least mitigate—the most substantial concerns. RV: Let's tackle the top five objections head-on.

1. "Primate research is irreplaceable for brain research." The brain is undeniably complex, but human-specific brain organoids and patient-derived iPSC neurons now replicate many features of human neurodevelopment and disease that primate models cannot, including human-specific gene expression patterns in cortical layers, as published in a 2025 Nature Biotechnology study. Decades of primate brain research have not produced a single cure for Alzheimer's; in contrast, human organoid models have already identified new therapeutic targets for TBK1 mutations in ALS.
2. "This will delay cures and cost human lives." The opposite is true in many cases. By eliminating misleading primate data, scientists can avoid late-stage clinical failures. A 2022 report by the Tufts Center for Drug Development estimated that every 10% reduction in false-positive preclinical results saves approximately $1.5 billion in drug development costs and accelerates time-to-market for successful drugs by 2–3 years.
3. "Nonhuman primates are similar to humans, so they are the best predictor." Similarity is not identity. The 90% failure rate in human trials, despite the use of primate models, proves that evolutionary proximity does not guarantee physiological fidelity, as noted above. In fact, the US Food and Drug Administration has approved several drugs since 2000 that were never tested on nonhuman primates but were validated solely on in vitro human data and pharmacokinetic modeling—examples include certain orphan drugs for rare genetic conditions.
4. "NAMs are not validated yet." While it is true that some organoid models are not yet fully standardised, the FDA Modernization Act 2.0 explicitly allows NAM-based data for IND (Investigational New Drug) applications, and the FDA's Alternative Methods Working Group has validated over 20 human-based models as predictively superior to NHP data for cardiotoxicity and hepatotoxicity since 2023, according to an FDA database update.
5. "It's a political move, not a scientific one." Politics and science are never fully separate, but the phasedown's architecture is based on data from the NIH's own intramural Comparative Animal Models program, which concluded in 2025 that NHP holdings were "underutilized and scientifically redundant" relative to emerging human platforms. The policy is supported by over 60 scientific societies, including the American Society for Cell Biology, who have issued statements endorsing the transition.

These objections are understandable given the long-standing inertia of animal-based research, but they do not withstand close scrutiny against the current evidence. The phasedown includes carve-outs for genuinely decadal challenges, but the default assumption now rightly favors human-based methods.

The regional angle: What it means for the US, UK, Canada, Australia, and beyond

The NIH phasedown is a US federal policy, but its shockwaves are global, and English-speaking countries are reacting at different speeds and with different strategies. In the United States, the phasedown is the most aggressive, with the full 2030 target now statutory as part of the NAMs Integration Act of 2025. In contrast, the United Kingdom has adopted a more gradualist approach: the Home Office's Animals in Science Regulation Unit reported a 34% drop in NHP procedures from 2020 to 2025, but no formal phasedown target has been set, although a 2026 consultation is underway to consider following the NIH's model. Canada has seen a grassroots shift, with the Canadian Council on Animal Care announcing in February 2026 that they will now require a human-based alternatives assessment for all NHP grant proposals, mirroring the NIH's Phase 1 audits, yet without federal funding increases for NAMs. Australia stands out as the most hesitant: the National Health and Medical Research Council has maintained its NHP support, citing a lack of local organoid manufacturing capacity, but a 2026 public petition with 80,000 signatures has forced a senate inquiry into primate research, according to the Australian Broadcasting Corporation.

For English-speaking readers, this regional variation is critical because it influences where funding flows and where scientific talent migrates:

• For American scientists: The NIH's new NAM Innovation Hubs are your best resource for transition support, and you can cite the NIH phasedown in grant applications for human-based work to see expedited review (20% faster review cycle, per NIH policy).
• For UK or Canadian researchers: You can leverage the US precedent to push your own funders, such as UKRI or CIHR, to adopt similar policies. Highlighting the competitive risk of falling behind is effective—US labs are already recruiting European primate postdocs to lead organoid projects.
• For Australian researchers: The institutional resistance may be frustrating, but there is an opportunity to be a regional NAM leader. The Pacific region lacks a dedicated organoid repository, so a collaborative initiative between Australian universities and non-profits could secure international funding, especially from philanthropic sources like the Open Philanthropy Project, which has committed $50 million to NAM research globally.

Beyond these four countries, the ripple effect reaches the European Union, where a 2025 European Commission directive encourages member states to reduce NHP use by 50% by 2030, and the NIH policy was specifically cited as a cross-border precedent in a June 2026 EU Parliament working paper. In India and China, where NHP research is still growing, the US scientific retreat may create a vacuum—but also an opportunity for those countries to skip ahead to human-based methods if they invest in the very technologies the NIH is now funding. For any English-speaking advocate, the message is simple: the US is the bellwether, and its policy creates a lever for change in your own country.

What can you do next? Practical actions for readers

You don't have to be a scientist or an investor to support a smooth and successful transition away from primate research. Here are five systematic steps you can take, from low-effort to high-impact, regardless of where you live.

• 🌱 Educate yourself and others: Read the full text of the NAMs Integration Act of 2025 (it's public record) and bookmark the NIH's own "Priority NAMs" web portal. Share one peer-reviewed study on human-based models (like the Alzheimer's organoid work) on your social media, with a quote from Dr. Vallas's interview. Over 300,000 users followed the #BanNHPTests hashtag in September 2026, and counterspeech from ethical scientists is crucial.
• ✅ Contact your elected representatives: In the US, write to your representative and senators thanking them for the phasedown, and ask that they fully fund the NIH's NAM Innovation Hubs next year. In the UK, Canada, or Australia, write to your health minister or your MP/MHA and explicitly reference the US policy as evidence that a transition is feasible. A one-page letter with the 90% failure stat is statistically more effective than a generic form,
• ♻️ Donate to NAM-focused non-profits: Organizations like the Physicians Committee for Responsible Medicine, the Nonhuman Rights Project, and the Center for Contemporary Sciences are actively funding alternatives. Even a small recurring donation supports validation studies for organoids and chips.
• 🧪 Support companies using human-based testing: Vote with your dollars by buying from pharmaceutical and cosmetics companies that have signed the industry pledge to eliminate NHP testing by 2035 (a list is available at the Freedom of Information clearinghouse). For cosmetics, choose cruelty-free certified brands, which legally cannot use any animal testing in the EU and US.
• 📣 Host a community screening or webinar: The following month, organize a small gathering (virtual or in-person) to watch Dr. Vallas's recent TED-style talk, "The End of the Primate Era," and"

Read next

• Vegan Diets & Climate Change: IPCC 2026 Case Study
• Cosmetic Animal Testing Bans vs REACH: The 2026 Conflict
• Ethical Wool Alternative Trends in Canada: Why We Must Move On